SonoSite Begins Customer Shipments of TITAN Upgrade for Cardiology/Shared Services Capabilities.

BOTHELL, Wash. -- Upgrade Provides Complete Capabilities for Echo Studies; Addresses $460 Million International Shared Services Market

SonoSite, Inc. (Nasdaq:SONO), the worldwide leader in high-performance, hand-carried ultrasound, said today that it has begun customer shipments of cardiology/shared service capabilities for the TITAN(TM) system, the company's most advanced, high-resolution, hand-carried system.

"This upgrade represents our fourth major expansion of the TITAN system's capabilities since its introduction a little over a year ago," said Kevin M. Goodwin, SonoSite president and CEO. "This latest release enables physicians to perform full echocardiography and vascular studies in the clinic or at the point-of-care, allowing for earlier diagnosis and treatment. It also addresses the need of many of our international customers who require a shared service system that can perform both radiology and cardiology examinations. The shared service market is estimated to account for at least 20% of the $2.3 billion international ultrasound market."

The TITAN system utilizes SonoSite's proprietary ASIC (Application Specific Integrated Circuit) technology to integrate millions of transistors onto one circuit, thereby providing exceptional imaging performance in a highly compact and durable design. Weighing only 7.7 pounds (3.5 kg.), the TITAN system boots up in less than 12 seconds, is easy to use and can be hand carried to wherever it is needed to immediately deliver patient care efficiently and effectively.

The TITAN 2.2 cardiology upgrade offers full cardiac and vascular calculation packages, pulsed and steerable continuous wave Doppler, Tissue Harmonic Imaging, velocity-based color Doppler and M-Mode. SonoSite also expanded the system's DICOM capabilities in this upgrade with the addition of DICOM Modality Worklist. These features are typically found on larger, more expensive ultrasound systems. The TITAN system has all the capabilities necessary to perform echocardiography studies that meet the standards required by payers for a complete echocardiography examination.

Introduced in May 2003 for multiple imaging applications, the TITAN system has gained rapid acceptance in both the United States and international markets and now accounts for approximately 50% of SonoSite's revenues. Prior upgrades have added enhanced connectivity as well as expanded capabilities for the radiology, vascular and Ob/gyn markets.

Cardiovascular disease is the leading cause of death in the United States and Europe. Moreover, according to the U.S. Department of Health and Human Services, it is estimated that more than one million Americans will die of cardiovascular disease in 2004. Prompt and accurate diagnosis of cardiovascular disease is critical to improving a patient's prognosis.

About SonoSite

SonoSite, Inc. (www.sonosite.com), headquartered near Seattle, is the innovator and worldwide market leader in high-performance, hand-carried ultrasound technology. By creating modular, mobile systems that meet customer needs, SonoSite is removing barriers to the use of ultrasound across medicine and positively impacting the cost-effectiveness and efficiency of ultrasound use. With more than 15,000 units sold worldwide since 1999, SonoSite's products have become known for exceptional durability with a high design value.

Forward-looking Information and the Private Litigation Reform Act of 1995

Certain statements in this press release relating to the market acceptance of our products, possible future sales relating to expected orders, and our future financial and operations results are "forward-looking statements" for the purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on the opinions and estimates of our management at the time the statements are made and are subject to risks and uncertainties that could cause actual results to differ materially from those expected or implied by the forward-looking statements. These statements are not guaranties of future performance and are subject to known and unknown risks and uncertainties and are based on potentially inaccurate assumptions. Factors that could affect the rate and extent of market acceptance of our products, the receipt of expected orders, and our financial performance include our ability to accurately forecast customer demand for our products, our ability to manufacture and ship our systems in a timely manner to meet customer demand, timely receipts of regulatory approvals to market and sell our products, the willingness of healthcare providers who do not currently use ultrasound to use ultrasound, the extent to which healthcare insurers reimburse providers for ultrasound procedures, regulatory changes in various national health care markets, constraints in government and public health spending, the ability of our distribution partners to market and sell our products, as well as other factors described under the heading, "Important Factors that May Affect Our Business, Our Results of Operating and Our Stock Price," included in our latest periodic report filed with the Securities and Exchange Commission. We caution readers not to place undue reliance upon these forward-looking statements that speak only as to the date of this release. We undertake no obligation to publicly revise any forward-looking statements to reflect new information, events or circumstances after the date of this release or to reflect the occurrence of unanticipated events.

TITAN is a trademark of SonoSite, Inc.